SEC 8-K
SEC 8-K: Item 5.02, 5.07
Official SEC filing update. Items: 5.02, 5.07.
Item 5.02, 5.07Accession 0001628280-26-040812
BioMarin Pharmaceutical (BMRN) Financials, Dividends & Stock Info
Explore comprehensive financial data for BioMarin Pharmaceutical, provided completely free. Analyze revenue, net income, profit margins, dividend history, and key financial ratios to make informed investment decisions.
Data as of (571 days ago)|Source: SEC EDGAR
The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results.
Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing. About · Methodology
BMRNHealth Care
BioMarin Pharmaceutical (BMRN) is a biotechnology company. The company reports annual revenue of $3.1B and net income of $520M. Its profit margin is 16.8%.
BioMarin Pharmaceutical Key Financials(TTM Est.)
Revenue (TTM)↑ 12.9%
$3.1B
Net Income (TTM)↓ 18.3%
$520.4M
Profit Margin
16.8%
Top 54% in sector
Return on Equity
8.6%
Top 73% in sector
Data from SEC EDGAR filings. TTM = Trailing Twelve Months.
BioMarin Pharmaceutical Financial Health ScoreFY2025
0/100
Good overall health with some areas for improvement
+2 pts YoYProfitability63Liquidity70Growth80Cash Flow100Efficiency40
This Financial Health Score is a proprietary metric calculated from SEC EDGAR filings for educational and informational purposes only. It does not constitute investment advice or a recommendation to buy or sell any security. Results vary significantly by industry. Conduct your own research before making investment decisions.
Data Highlights
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
BioMarin Pharmaceutical Official SEC Updates
Official filing updates from SEC EDGAR. Billiver stores internal evidence snapshots for verification, but this page links to the SEC source instead of republishing full filing text.
Open SEC filing
SEC 10-Q
SEC 10-Q
Official SEC filing update.
10-QAccession 0001048477-26-000008
SEC 8-K
SEC 8-K: Item 2.02, 9.01
Official SEC filing update. Items: 2.02, 9.01.
Item 2.02, 9.01Accession 0001048477-26-000006
SEC 8-K
SEC 8-K: Item 1.01, 2.01, 2.03, 7.01, 9.01
Official SEC filing update. Items: 1.01, 2.01, 2.03, 7.01, 9.01.
Item 1.01, 2.01, 2.03, 7.01, 9.01Accession 0001193125-26-179243
SEC 8-K
SEC 8-K: Item 8.01
Official SEC filing update. Items: 8.01.
Item 8.01Accession 0001193125-26-173770
Source: SEC EDGAR · 5 filings
Informational only. Not investment advice.
BioMarin Pharmaceutical Recent Events
Leadership Change
Shareholder Vote
Earnings Results
Acquisition or Disposition
Material Agreement
Source: SEC EDGAR 8-K Filings
5-Year Revenue & Net Income Trend
Chart shows fiscal year data from SEC EDGAR filings. Hover over data points for details.
As of FY2025 · SEC 10-K · Updated Jul 2, 2026
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
- Industry
- Biotechnology
Valuation
Valuation Data UnavailablePrice-based valuation metrics (P/E, P/B) require real-time stock price data which is not included in SEC filings.
Benjamin Graham: Graham recommended P/E ratio not exceed 15 for reasonable valuation. Understanding valuation metrics
Profitability
Positive MarginsROE8.6%
vs 14.8% sector median / 21.8% avg
▼
Generates $8.6 in profit for every $100 of shareholder equity. Higher than 27% in Health Care.
Profit Margin16.8%
vs 18.1% sector median / 15.0% avg
▼
Keeps 17 cents of every dollar in revenue as profit. Higher than 46% in Health Care.
Revenue (TTM)*$3.1B
4th consecutive year of revenue growth.
Net Income (TTM)*$520M
* Some quarterly data is missing. Values are calculated based on annual report figures.
Profit margin of 16.8% is above 10%.
Warren Buffett: Buffett looks for consistent ROE above 20% as a sign of competitive advantage. How to evaluate profitability
Financial Health
Balance Sheet Data LimitedInsufficient data to assess financial health.
Peter Lynch: Lynch: normal balance sheet has 75% equity, 25% debt. Understanding financial health
Dividend
Dividend Data UnavailableDividend yield data is not available from SEC filings. Check the company's investor relations page for dividend information.
As of FY2025 · SEC 10-K · Updated Jul 2, 2026
BioMarin Pharmaceutical 10-Year Revenue, Profit & Cash Flow History
Annual Financials
FY2025 - FY2016| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.2B(+12.9%) | $2.9B(+18.0%) | $2.4B(+15.4%) | $2.1B(+13.5%) | $1.8B(-0.8%) | $1.9B(+9.2%) | $1.7B(+14.3%) | $1.5B(+13.5%) | $1.3B(+17.6%) | $1.1B(+25.5%) |
| Net Income | $348.9M(-18.3%) | $426.9M(+154.6%) | $167.6M(+18.4%) | $141.6M(+320.9%) | $-64,080,000(-107.5%) | $854.0M(+3681.1%) | $-23,848,000(+69.1%) | $-77,211,000(+34.0%) | $-117,042,000(+81.4%) | $-630,210,000(-266.8%) |
| Total Assets | $7.6B | $7.0B | $6.8B | $6.4B | $6.0B | $5.8B | $4.7B | $4.4B | $4.6B | $4.0B |
| Total Debt | - | - | - | - | - | - | - | - | - | - |
| Total Equity | $6.1B | $5.7B | $5.0B | $4.6B | $4.3B | $4.1B | $3.1B | $3.0B | $2.8B | $2.8B |
| Profit Margin | 10.8% | 15.0% | 6.9% | 6.8% | -3.5% | 45.9% | -1.4% | -5.2% | -8.9% | -56.4% |
| ROE | 5.7% | 7.5% | 3.4% | 3.1% | -1.5% | 20.8% | -0.8% | -2.6% | -4.2% | -22.8% |
| ROA | 4.6% | 6.1% | 2.5% | 2.2% | -1.1% | 14.6% | -0.5% | -1.7% | -2.5% | -15.7% |
Quarterly Financials
Last 8 quarters| Metric | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $745.1M | $776.1M | $825.4M | $745.1M | $745.7M | $712.0M | $648.8M | $581.3M |
| Net Income | $185.7M | $-30,744,000 | $240.5M | $185.7M | $106.1M | $107.2M | $88.7M | $40.4M |
| Total Assets | $7.6B | $7.6B | $7.5B | $7.1B | $6.9B | $7.1B | $6.9B | $6.8B |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026
Smart Money Insight
3 insiders sold shares worth $3.0M, despite revenue growth of +12.9% YoY. Divergence signal strength: 50/100.
Source: SEC EDGAR Form 4, 13F, 10-K/10-Q (as of 2026-03-28)
Insider Trading
Loading chart...
Loading transactions...
Source: SEC EDGAR Form 4 filings. Only purchase (P) and sale (S) transactions shown.
BioMarin Pharmaceutical Free Cash Flow & Dividend Coverage
Free Cash Flow
$725.0M
FY2025
FCF Margin
22.5%
FCF / Revenue
Operating Cash Flow
$828.0M
Cash from operations
FCF / Net Income
2.08x
Quality earnings
Generates approximately $2M in free cash flow per day.
Cash Flow History
FY2016 - FY2025| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | -$227.8M | -$8.8M | $20.2M | $48.3M | $85.4M | $304.5M | $175.9M | $159.3M | $572.8M | $828.0M |
| CapEx | -$148.4M | -$199.2M | -$144.6M | -$145.0M | -$114.3M | -$95.6M | -$121.0M | -$96.7M | -$85.4M | -$103.0M |
| Free Cash Flow | -$376.2M | -$208.0M | -$124.4M | -$96.8M | -$28.9M | $209.0M | $54.9M | $62.6M | $487.4M | $725.0M |
| FCF Margin | -33.7% | -15.8% | -8.3% | -5.7% | -1.6% | 11.3% | 2.6% | 2.6% | 17.1% | 22.5% |
Source: SEC EDGAR 10-K filings. FCF = Operating Cash Flow - Capital Expenditures. Free cash flow guide
As of FY2025 · SEC 10-K · Updated Jul 2, 2026
BioMarin Pharmaceutical Risk Factors
Company-disclosed SEC risk factors
Risk factors are disclosed by the company in its SEC Form 10-K, Item 1A. Billiver does not classify or summarize company-specific legal, operational, financial, or market risks here.
Sector context: Health Care. This is not a Billiver risk assessment for BMRN.
Source note: the SEC Form 10-K includes Item 1A, "Risk Factors." The full risk-factor text should be read from the company’s own SEC filing.
BioMarin Pharmaceutical FAQ
What is BioMarin Pharmaceutical's annual revenue?
BioMarin Pharmaceutical (BMRN) reported $3.1 billion in trailing twelve-month (TTM) revenue. This financial data is compiled from SEC EDGAR 10-K filings.
Is BioMarin Pharmaceutical profitable?
Yes, BioMarin Pharmaceutical is profitable with a 16.8% net profit margin and $520 million in net income (TTM). All figures from SEC EDGAR 10-K filings.
Does BioMarin Pharmaceutical pay dividends?
No, BioMarin Pharmaceutical (BMRN) does not currently pay dividends to shareholders.
What is BioMarin Pharmaceutical's financial health score?
BioMarin Pharmaceutical has a financial health score of 70/100 (Grade: B), evaluating profitability, solvency, liquidity, and growth based on SEC EDGAR data.
How many years of BioMarin Pharmaceutical financial data are available?
10 years of financial data are available for BioMarin Pharmaceutical from FY2016 to FY2025. All figures are compiled from SEC EDGAR 10-K filings.